An atypical case of a pulmonary mass in an immunocompromised patient.
Aged
Azathioprine
/ adverse effects
Biopsy
Bronchoscopy
Chest Pain
Crohn Disease
/ drug therapy
Dyspnea
Endosonography
Female
Humans
Immunocompromised Host
Immunosuppressive Agents
/ adverse effects
Lung Neoplasms
/ chemically induced
Lymphomatoid Granulomatosis
/ chemically induced
Positron Emission Tomography Computed Tomography
Crohn’s disease
Epstein-barr virus
Pulmonary lymphomatoid granulomatosis
case report
immunosuppression
Journal
Acta clinica Belgica
ISSN: 2295-3337
Titre abrégé: Acta Clin Belg
Pays: England
ID NLM: 0370306
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
20
8
2019
medline:
3
8
2021
entrez:
20
8
2019
Statut:
ppublish
Résumé
Pulmonary lymphomatoid granulomatosis (PLG) is a rare angiocentric and angiodestructive EBV-associated lymphoproliferative disorder which almost always affects the lungs. PLG is more commonly diagnosed in patients with immunodeficiency and is associated with Epstein-Barr virus (EBV). 'Drug induced PLG' or 'iatrogenic immunodeficiency-associated lymphoproliferative disorder' is a special form of PLG described in patient with inflammatory bowel diseases treated with Azathioprine. We report a case of drug-induced PLG in a 68-year-old patient with Crohn's disease presenting with pain at the right hemithorax, fatigue and shortness of breath with a pulmonary mass. Although initial diagnostic findings were misleading, an open lung biopsy eventually led to the diagnosis of drug-induced PLG. The diagnosis of PLG is challenging because the disease is rare and the histological features can be very subtle. Correct diagnosis relies on histopathology and immunohistochemical staining and EBV RNA in situ hybridization with sampling of large and different amounts of pathologic tissue in the hands of expert pathologists. In drug-induced PLG specifically, withdrawal of the immunosuppressive agent can lead to disease regression.
Identifiants
pubmed: 31423951
doi: 10.1080/17843286.2019.1655232
doi:
Substances chimiques
Immunosuppressive Agents
0
Azathioprine
MRK240IY2L
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM